Peter ten Dijke
Has grant
Research Interests
Explore related searches
Contact this professor
Get a free first email built on one of their papers, ready for you to edit and send yourself.
Recent Grants
Grant: Close
Use of patient-relevant human lung epithelial cell models to study acute and long-term effects of COVID-19
Open Date: 2020-01-01
Close Date: 2022-01-01
Grant: Close
Finding the CRIPTOnite for the joints; Cripto, a member of the TGF-b superfamily as a novel target for osteoarthritis
Open Date: 2014-01-01
Close Date: 2017-01-01
Grant: Close
Cancer Genomics Center Netherlands
Open Date: 2013-01-01
Close Date: 2022-01-01
Grant: Close
Pulmonary Hypertension and associated Right Heart Failure (Phaedra): breaking the vicious circle
Open Date: 2013-01-01
Close Date: 2019-01-01
Grant: Close
ITN training network grant from European Union ‘Targeting TGF-b in liver disease’
Open Date: 2012-01-01
Close Date: 2016-01-01
Articles (10)
Year:
2023
Year:
2023
The genetic circuits that allow cancer cells to evade immune killing via epithelial mesenchymal plasticity remain poorly understood. Here, we showed that mesenchymal-like (Mes) KPC3 pancreatic cancer cells were more resistant to cytotoxic T lymphocyte (CTL)–mediated killing than the parental epithelial–like (Epi) cells and used parallel genome-wide CRISPR screens to assess the molecular underpinnings of this difference. Core CTL-evasion genes (such as IFN-γ pathway components) were clearly evident in both types. Moreover, we identified and validated multiple Mes-specific regulators of cytotoxicity, such as Egfr and Mfge8. Both genes were significantly higher expressed in Mes cancer cells, and their depletion sensitized Mes cancer cells to CTL-mediated killing. Notably, Mes cancer cells secreted more Mfge8 to inhibit proliferation of CD8 + T cells and production of IFN-γ and TNFα. Clinically, increased Egfr and Mfge8 expression was correlated with a worse prognosis. Thus, Mes cancer cells use Egfr-mediated intrinsic and Mfge8-mediated extrinsic mechanisms to facilitate immune escape from CD8 + T cells.
Year:
2023
Despite advances in treatment for metastatic melanoma patients, patients with liver metastasis have an unfavorable prognosis. A better understanding of the development of liver metastasis is needed. The multifunctional cytokine Transforming Growth Factor β (TGF-β) plays various roles in melanoma tumors and metastasis, affecting both tumor cells and cells from the surrounding tumor microenvironment. To study the role of TGF-β in melanoma liver metastasis, we created a model to activate or repress the TGF-β receptor pathway in vitro and in vivo in an inducible manner. For this, we engineered B16F10 melanoma cells to have inducible ectopic expression of a constitutively active (ca) or kinase-inactive (ki) TGF-β receptor I, also termed activin receptor-like kinase (ALK5). In vitro, stimulation with TGF-β signaling and ectopic caALK5 expression reduced B16F10 cell proliferation and migration. Contrasting results were found in vivo; sustained caALK5 expression in B16F10 cells in vivo increased the metastatic outgrowth in liver. Blocking microenvironmental TGF-β did not affect metastatic liver outgrowth of both control and caALK5 expressing B16F10 cells. Upon characterizing the tumor microenvironment of control and caALk5 expressing B16F10 tumors, we observed reduced (cytotoxic) T cell presence and infiltration, as well as an increase in bone marrow-derived macrophages in caALK5 expressing B16F10 tumors. This suggests that caALK5 expression in B16F10 cells induces changes in the tumor microenvironment. A comparison of newly synthesized secreted proteins upon caALK5 expression by B16F10 cells revealed increased secretion of matrix remodeling proteins. Our results show that TGF-β receptor activation in B16F10 melanoma cells can increase metastatic outgrowth in liver in vivo, possibly through remodeling of the tumor microenvironment leading to altered infiltration of immune cells. These results provide insights in the role of TGF-β signaling in B16F10 liver metastasis and could have implications regarding the use of TGF-β inhibitors for the treatment of melanoma patients with liver metastasis.
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2022
Year:
2022
Collaborators (11)
Peter van Veelen
Leiden University Medical Center
Laila Ritsma
Leiden University Medical Center
Birol Cabukusta
Group leader / Assistant professor
University of Maastricht
Mikael Sellin
Professor
Uppsala University
Katarina Madunić
Leiden University Medical Center
Ferry Ossendorp
Group Leader, Professor
Leiden University Medical Center
Román González-Prieto
Leiden University Medical Center
Alfred Vertegaal
Professor
Leiden University
Rob C. Hoeben
Leiden University Medical Center
Sjoerd H. van der Burg
Leiden University Medical Center
Jens Eriksson
Uppsala University
Make your next move.
Prepare your application
Review drafts before you send them.